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Abstract
Background: MEIS2 has been identified as one of the key transcription factors in the gene regulatory
network in the development and pathogenesis of human cancers. Our study aims to identify the regulatory
mechanisms of MEIS2 in hepatocellular carcinoma (HCC), which could be targeted to develop new
therapeutic strategies.
Methods: The variation of MEIS2 levels were assayed in a cohort of HCC patients. The proliferation, clone-
formation, migration, and invasion abilities of HCC cells were measured to analyze the effects of MEIS2C
and MEIS2D (MEIS2C/D) knockdown with small hairpin RNAs in vitro and in vivo. Chromatin immunoprecipitation
(ChIP) was performed to identify MEIS2 binding site. Immunoprecipitation and immunofluorescence assays were
employed to detect proteins regulated by MEIS2.
Results: The expression of MEIS2C/D was increased in the HCC specimens when compared with the
adjacent noncancerous liver (ANL) tissues. Moreover, MEIS2C/D expression negatively correlated with the
prognosis of HCC patients. On the other hand, knockdown of MEIS2C/D could inhibit proliferation and
diminish migration and invasion of hepatoma cells in vitro and in vivo. Mechanistically, MESI2C activated Wnt/β-
catenin pathway in cooperation with Parafibromin (CDC73), while MEIS2D suppressed Hippo pathway by promoting
YAP nuclear translocation via miR-1307-3p/LATS1 axis. Notably, CDC73 could directly either interact with MEIS2C/β-
catenin or MEIS2D/YAP complex, depending on its tyrosine-phosphorylation status.
Conclusions: Our studies indicate that MEISC/D promote HCC development via Wnt/β-catenin and Hippo/
YAP signaling pathways, highlighting the complex molecular network of MEIS2C/D in HCC pathogenesis. These
results suggest that MEISC/D may serve as a potential novel therapeutic target for HCC.
Keywords: HCC, MEIS2, Alternative splicing, Wnt, Hippo, CDC-73
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: xl@pennmedicine.upenn.edu; huqzhang@mail.xjtu.edu.cn
†Lei Guan, Ting Li and Nanping Ai contributed equally to this work.
7Department of Pathology and Laboratory Medicine, Perelman School of
Medicine, University of Pennsylvania, 712 Stellar-Chance Laboratories, 422
Curie Blvd, Philadelphia, PA 19104, USA
1The Key Laboratory of Biomedical Information Engineering of Ministry of
Education, School of Life Science and Technology, Xi’an Jiaotong University,
28, Xianning West Road, Xi’an 710049, Shaanxi, People’s Republic of China
Full list of author information is available at the end of the article
Guan et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:417 
https://doi.org/10.1186/s13046-019-1417-3
Background
Hepatocellular carcinoma (HCC) is a primary liver can-
cer with high mortality. It is one of the most common
malignancies in the world, especially in Asia, Africa, and
Southern Europe [1]. Although some progress has been
made in the study of the pathogenesis of HCC in recent
years, the long-term survival rate of HCC patients is still
not optimistic. Therefore, further study of the molecular
mechanism of liver cancer is needed.
Meis homeobox 2 (MEIS2) belongs to the three amino
acid loop extension (TALE) superfamily [2]. TALE
homeobox genes represent a subset of the homeobox gene
family. TALE genes are crucial for normal development of
the nervous system [3–5]. In vertebrates, TALE homeo-
proteins are represented by the PBX and MEIS/PREP
subfamilies [6–8]. Most of them have also been implicated
in tumorigenesis. Accumulating research suggests an
oncogenic role for MEIS2 in the development of neuro-
blastoma, leukemia, bladder, prostate, and ovarian cancer
[9–14]. It has been shown that MEIS2 is essential for the
survival and proliferation of neuroblastoma cell by tran-
scriptional control of M-phase progression [9]. Alternative
splicing is important for posttranscriptional regulation of
MEIS2. Because of the sequence difference of C-terminal
due to alternative splicing, there are two mainly alterna-
tively spliced isoforms of MEIS2, MEISI2A and MEIS2B
(MEIS2A/B) and MEISI2C and MEIS2D (MEIS2C/D). It
has been reported that MEIS2 affects neuroblastoma pro-
liferation and differentiation in opposing ways, depending
on the relative expression of two of its alternative splice
isoforms [15]. Nevertheless, the role of MEIS2 in HCC
remains poorly defined.
Previous studies have shown that miR-1307 may be a
therapeutic target for ovarian cancer [16]. Also, miR-
1307 could promote the proliferation of prostate cancer
through targeting FOXO3 [17]. MiR-1307-3p is origi-
nated from the 3′ end of pre-miR-1307, and increased in
breast cancer patients’ serum [18, 19]. However, the up-
stream regulators of miR-1307 during tumorigenesis and
its specific role in HCC remain unclear.
The Hippo signaling pathway inhibition promotes
cirrhosis and tumorigenesis in liver [20]. Yes-associated
protein (YAP) is a nuclear effector of the cell-density
sensing Hippo pathway and it interacts with Src hom-
ology phosphotyrosine phosphatase 2 (SHP2), which
controls cell proliferation and survival. It has been
shown that the tumorigenic role of YAP in HCC re-
quires SHP2. Moreover, on tyrosine dephosphorylation
by SHP2, Parafibromin (cell division cycle 73, CDC73)
acquires the ability to stably bind to β-catenin. The
CDC73/β-catenin complex induces expression of Wnt
target genes, which promote HCC progression [21–24].
Nevertheless, the specific regulatory network that con-
trols YAP and SHP2 in HCC still need to be identified.
To investigate the role of MEIS2 in HCC, we exam-
ined the expression of MEIS2 in HCC samples and adja-
cent noncancerous livers (ANL) and found that the level
of two alternatively spliced MEIS2 isoform, MEIS2C/D,
are up-regulated in HCC tissues. In addition, MEIS2C/D
are associated with poor prognosis in HCC patients.
Importantly, knockdown of MEIS2C/D could inhibit
proliferation and diminish migration and invasion of
hepatoma cells in vitro and in vivo. Mechanistically,
MEIS2D suppressed Hippo pathway by promoting YAP
nuclear translocation via miR-1307-3p/LATS1 axis,
while MESI2C activated Wnt/β-catenin pathway in
cooperation with CDC73. Interestingly, the interaction
between CDC73 and MEIS2C/β-catenin or MEIS2D/
YAP depend on its tyrosine-phosphorylation status. Col-
lectively, our studies indicate that MEIS2C/D promote




We collected 118 paired tumorous and adjacent noncan-
cerous liver samples from April 2016 to MAY 2018 in
The First Affiliated Hospital of Xi’an Jiaotong University
and Xijing Hospital. Detailed clinical pathological pa-
rameters were listed in Additional file 1: Table S1. The
average age was 52.6 years, and ages range from 38 to
75. A total of 59 males and 59 females were included.
There were no patients who received chemotherapy or
radiotherapy before surgery excision. Informed consent
was obtained from each patient, and the study protocol,
which conformed to the ethical guidelines of the 1975
Declaration of Helsinki, was approved by the Institute
Research Ethics Committee at The First Affiliated Hos-
pital of Xi’an Jiaotong University and Xijing Hospital.
Cell culture
HCC-LM3 and MHCC97H cell were routinely culture in
DMEM medium supplemented with 1X MEM, 1X So-
dium pyruvate, 1X Glutamine + 25 mM HEPES +1X 2-
ME (from 55mM stock 1000X) + 10% FBS and antibi-
otics. All cultures were maintained in a humidified 5%
CO2 incubator at 37 °C, and routinely passaged when
80–90% confluent.
RNA isolation, reverse transcription PCR (RT-PCR) and
quantitative real-time RT-PCR (qRT-PCR)
Total RNA was extracted using TRIzol (Invitrogen) ac-
cording to the manufacturer’s instructions. Reverse
transcription was carried out using oligo-dT primers.
MiR-1307-3p mRNA levels were detected by using qRT-
PCR. 18 s RNA and U6 were used as internal controls.
Real-time PCR was performed in an Applied Biosystems
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7500 system using Power SYBR Green PCR Master Mix
(Applied Biosystems).
Western blot
The cells were lysed in RIPA buffer in presence of prote-
ase inhibitor cocktail (Roche). Whole cell lysates were pre-
pared and subjected to 12% SDS-PAGE and transferred to
NC membrane (Bio-Red). The membranes were incubated
overnight at 4 °C with the specific antibodies. Membranes
were washed and incubated for 1 h at room temperature
with secondary antibody conjugated with peroxidase.
Membrane-bound immune complexes were detected
using Super ECL detection reagent on Amersham Imager
600(GE Healthcare).
Cell viability assay
Cell viability was analyzed using the Cell Counting Kit-8
(CCK-8) (Dojindo). Cells at a density of 5 × 102/well
were seeded into 96-well plates and cultured in 100 μl of
DMEM containing 10% FBS for 5 days. Ten microliter of
CCK8 solution was added to each plate, and the cells
were incubated for 3 h at 37 °C. The absorbance value
(OD) of each well was measured at 450 nm.
Colony formation assay
Cells were plated in 6-well culture plates. After incubation
for 12 days at 37 °C, the cells were washed twice with PBS
and stained with 0.1% crystal violet solution. The number
of colonies was counted under a microscope.
Migration and invasive assays
Cell motility was assessed by cell invasion and migration
assays using Transwell chambers with or without Matri-
gel (BD, Biosciences). Cells in medium without FBS were
seeded on Transwell chambers with or without Matrigel
and incubated at 37 °C for 15 h. Medium containing 2%
FBS was put in the lower chamber. The invasive cells
attached to the lower surface of the membrane insert
were fixed, stained using Giemsa and quantified.
ChIP
ChIP assay was carried out using Chromatin Immuno-
precipitation Kit (Sigma-Aldrich) according to the man-
ufacturer’s protocol. IP was performed using specific
antibodies, anti-RNA Pol II or normal IgG. Experiments
were repeated three times independently.
Promoter luciferase assay
Cells were transfected with reporter constructs contain-
ing the promoter together with expression vector or
empty vector using Lipofectamine 3000 (Thermo Fisher
Scientific). After 48 h, the luciferase activities of whole
cell lysates were measured using the dual-luciferase
reporter assay system (Promega). For all samples, the
assays were repeated at least three times.
Xenograft and metastasis assays
All animal studies were approved by the Institutional
Animal Care and Use Committee of Xi’an Jiaotong Uni-
versity (Xi’an, China).Eight-week-old male nude mice
Nude mice were housed five mice per cage in a specific
pathogen-free room. HCC-LM3 (1.0 × 106 cells/mouse)
or MHCC97H (1.0 × 107 cells/mouse) shMEIS2C/D and
control cell lines were subcutaneously injected into the
mice to form the xenograft model. The mice were ran-
domly divided into indicated groups (5–10 mice/group)
before inoculation, and double-blinded evaluation was
performed. Mouse survival was analyzed using a survival
analysis. The mice were sacrificed at endpoint, tumors
and their lungs were removed. Tumor volume and
weight were measured. To evaluate the potential of the
cells to metastasize to livers, nude mice spleens were
inoculated with shMEIS2C/D or control HCC-LM3 cells
(8 × 105), and the metastatic tumor colonies in the liver
were measured 12 weeks later.
Statistics analysis
Data analysis was performed using the SPSS software
version 16. Survival of distinct subgroups of HCCs were
compared by Kaplan-Meier and log-rank analyses. Re-
sults were presented as mean ± s.d. χ2-Test and two-
tailed Student’s t-test were used to assess statistical
significance. P < 0.05 was considered statistically
significant.
Results
MEIS2C/D expression is significantly upregulated in HCC
and it correlates with poor prognosis
To determine whether MEIS2 has important roles in
liver cancer, we compared the expression of MEIS2
mRNA and protein in a cohort of 118 human HCCs and
their paired adjacent noncancerous liver (ANL) samples.
The results showed that MEIS2 mRNA was not signifi-
cantly changed in HCC tissues when compared with
ANL (Fig. 1a). Due to alternative splicing, there are four
MEIS2 isoforms with different C-termini. Skipping of
exon 12 results in a longer C-terminus, present in
isoforms MEIS2C/D, whereas inclusion of exon 12 intro-
duces an early stop codon and generates a distinct and
shorter C-terminus, termed MEIS2A/B (Fig. 1b). Strik-
ingly, when we investigated the protein level of different
MEIS2 isoforms in 18 random HCC and matched ANL
tissues, we found that MEIS2C/D is overexpressed in
these HCC tissues, whereas MEIS2A/B is not signifi-
cantly changed (Fig. 1c). Similarly, there is no significant
difference in the expression status of MEIS2A/B between
HCC and ANL tissues, whereas the mRNA level of
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MEIS2C/D was significantly increased in HCC tis-
sues (Fig. 1d). Next, we divided HCC patients into
low MEIS2C/D group and high MEIS2C/D group
based on their relative median mRNA expression
level of MEIS2C/D and compared 12 widely recog-
nized clinicopathological parameters in 118 HCC
specimens. Statistical analysis indicated that higher
MEIS2C/D expression level was not only signifi-
cantly associated with more advanced tumor stage
and differentiation, but also significantly associated
with tumor size and the presence of microvascular
invasion (Additional file 1: Table S1). These results
indicated that MEIS2C/D is associated with HCC
growth and metastasis. Furthermore, Kaplan-Meier’s
survival curves showed that the HCCs with a higher
MEIS2C/D expression had higher cumulative recur-
rence rates (CRR) after hepatectomy and worse over-
all survival (OS) (Fig. 1e). These results indicated
that MEIS2C/D might promote tumor progression of
HCC and that it could serve as a helpful prognostic
marker for HCC patients after hepatectomy.
Knockdown of MEIS2C/D inhibited proliferation and
metastasis of HCC cells in vitro
To further define the biological role of MEIS2C/D in
HCC, we designed short hairpin RNA and siRNA to
Fig. 1 MEIS2C/D are overexpressed in hepatocellular carcinoma tissues and associated with poor prognosis. a Quantitative reverse transcriptase
PCR (qRT-PCR) analysis showing the expression of MEIS2 in 118 pairs of HCC patient tissues compared adjacent noncancerous livers (ANL). b A
schematic drawing of four major splice subtypes of MEIS2 mRNA. Alternative splicing generated two mainly group of MEIS2 isoforms with
different C-terminal exon (exon12 vs. exon 13). c Western blot analysis of MEIS2 in 18 random HCC and paired ANL tissues. d Real-time PCR
analysis of MEIS2A/B (exon12) and MEIS2C/D (exon13) expression in HCC and matched ANL. e Prognostic significance assessed by Kaplan–Meier
estimates method and log-rank test. Comparison of the time to recurrence rate and overall survival by MESI2C/D expression
Guan et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:417 Page 4 of 14
Fig. 2 Knockdown MEIS2C/D inhibited growth and metastasis of HCC cells in vitro. a, b Expression of MEIS2C/D were measured by qRT-PCR and
western blot in HCC-LM3 and MHCC97H cells treated with shMEIS2C/D targeting MEIS2C/D (exon 13) or Scramble. c, d The in vitro proliferation
function of MEIS2C/D was measured by the CCK-8 Kit and colony-forming assay. The cells were seeded in 6-well plates. e, f Migration and
invasion were measured by Transwell assay coated with or without Matrigel in the indicated stable HCC cell lines. HCC cells were seeded in 12-
well plates. Representative images are shown (scalebar 100 μm). Experiments were repeated three times with similar results, and error bars
represent the mean ± SEM, *P < 0.05, **P < 0.001
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knockdown MEIS2C/D expression (Fig. 2a, b and
Additional file 1: Figure S1). MEIS2C/D mRNA and
protein expression in HCC cell lines (HCC-LM3 and
MHCC97H) were modulated by transfection with
shMEIS2. Afterwards, we examined the effect of
MEIS2C/D knockdown on HCC cells growth in vitro. By
using CCK-8 and colony formation assays (Fig. 2c, d),
we found that knockdown of MEIS2C/D markedly
inhibited proliferation in HCC cells. Furthermore,
matrigel-uncoated (for migration) or –coated (for inva-
sion) Transwell assays showed that HCCs migration and
invasion were effectively suppressed by MEIS2C/D
knockdown (Fig. 2e, f).
MEIS2C/D suppression impaired HCCs growth and
metastasis in vivo
To translate the in vitro findings in vivo, we first estab-
lished xenograft tumor in nude mice by subcutaneously
injecting shMEIS2C/D and control stable HCC cell
lines. After 6 weeks of tumor inoculation, shMEIS2C/
D cell-derived HCC-LM3 and MHCC97H tumors at
the subcutaneous implantation sites were smaller and
grew more slowly than those in the scramble group
(Fig. 3a, c). Next, we inoculated shMEIS2C/D HCC-
LM3 and control cells into mouse spleens to explore
their hepatic metastasis potentials in nude mice. After
12 weeks, we measured metastatic tumor colonies in
Fig. 3 Knockdown MEIS2C/D suppressed malignant behaviors of HCC cells in vivo. a Representative image showing xenografts in nude mice
were established by subcutaneous injection of shMEIS2C/D and control HCC-LM3 cell lines (n = 8). Comparisons of overall survival curves in mice
(n = 10). P values were calculated using the Log-rank test. b Representative image showing visible intrahepatic metastases in the HCC-LM3-
shMEIS2C/D and control groups (n = 5). c MHCC97H-shMEIS2C/D and control cells were injected subcutaneously in nude mice and tumor
volume was evaluated after injection (n = 6). Comparisons of overall survival curves in mice injection of MHCC97H-shMEIS2C/D and control
groups (n = 10). d Representative image and H&E stain showing spontaneous lung metastasis in matched subcutaneous nude mice model (n = 5)
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liver, and found that the group inoculated with HCC-
LM3 shMEIS2C/D cells showed fewer and smaller xe-
nografts in the liver than the control group (Fig. 3b).
In addition, the pulmonary metastasis rates in nude
mice with tumors derived from shMEIS2C/D-
MHCC97H cells were also significantly lower than
the corresponding control group (Fig. 3d). Collect-
ively, these findings suggested that MEIS2C/D is
capable of promoting HCC aggressive and metastatic
phenotype in vivo.
MEIS2D promotes miR-1307-3P expression in HCC
Although we have confirmed that MEIS2C/D could pro-
mote the progression and metastasis of HCC in vitro and
in vivo, the underlying molecular mechanism remains to
be explored. Given the findings that miR-1307-3p has been
implicated in tumorigenesis [18, 19], we hypothesized that
miR-1307-3p may as a potential target of MEIS2. Although
neither MEIS2 nor MEIS2A/B correlated with miR-1307-
3p expression in HCC, MEIS2C/D positively correlated
with the expression of miR-1307-3P (Fig. 4a). MEIS2 and
Fig. 4 MEIS2 regulated miR-1307-3p expression. a The correlation between the mRNA expression of MEIS2 and miR-1307-3p in HCC patient cohort.
Pearson’s correlation analysis was used. b miR-1307-3p expression were detected by qRT-PCR after transfection of indicated siRNA in HCC cell lines. c
The predicted putative MEIS2 binding site on miR-1307 promoter by using JASPAR (jaspar.genereg.net). d Dual luciferase reporter assays of various
recombinant miR-1307 promoter vectors were co-transfect with different isoforms of MEIS2 and its coactivator PBX1 in HEK293T cells. Relative
luciferase activity was determined by normalizing the activity of Firefly against Renilla luciferase. e ChIP assay was performed to examine the
association of MEIS2D and PBX1 with the potential MEIS2 binding site in different miR-1307 promoter regions (3 KB), as determined by qRT-PCR
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PBX1 are member of the TALE superfamily of homeodo-
mains, and PBX1 can also recognize and co-activate MEIS2
near the MEIS2 binding motif sequence. When we used
siRNA to knockdown the levels of MEIS2C/D or PBX1,
the expression of miR1307-3p drastically decreased
(Fig. 4b). Moreover, by sequence analysis, we found
that there are three putative MEIS2 binding sites in
the promoter of miR-1307 gene (Fig. 4c). To test
whether MEIS2 could activate the expression of miR-
1307 through these three loci, we constructed a series
of reporters containing these three locus sequences
and co-transfected HEK293T cells with expression
plasmids of four MEIS2 isoforms. Consistently, the
luciferase activity assay indicated that, when compared
with the other isoforms, MEIS2D could significantly
activate the activity of M2 +M3 and M1 +M2 +M3
reporter (Fig. 4d, Left panel). Furthermore, MEIS2D
and PBX1 could synergistically enhance the activity of
miR-1307 promoter (Fig. 4d, Right panel). To further
determine the binding site of MEIS2D and PBX1 on
miR-1307 promoter, we designed primers at the M1,
M2 and M3 loci of miR-1307 promoter and per-
formed ChIP assay. Our data confirmed that both
MEIS2D and PBX1 could bind to M2 site directly
(Fig. 4e and Additional file 1: Figure S2A). Notably,
MEIS2A/B knock down could suppress miR-1307-3p
expression and MEIS2B overexpression inhibited re-
porter of miR-1307 promoter (Fig. 4d, Additional file 1:
Figure S2B and S2C). Therefore, we theorized that the M2
site of miR-1307 promoter mediates the binding and tran-
scriptional activation of MEIS2D and PBX1 complex.
MEIS2C/D suppression inhibited nuclear accumulation of
YAP by miR-1307-3p/LATS1 axis
Alterations in the components of the Hippo signaling
pathway are reported to be associated with tumor progres-
sion in HCC [25, 26]. The central axis of the Hippo path-
way is a kinase cascade that includes MST1/2 and
LATS1/2. Interestingly, our results showed that 3′ un-
translated region (UTR) of LATS1 mRNA had putative
binding sequence for miR-1307-3p (Fig. 5a, Upper panel
from www.targetscan.org), indicating that LATS1 might
be a target gene of miR-1307-3p. In order to confirm this,
we transfected HEK293T cells with miR-1307-3p mimics
and detected the luciferase activity of LATS1 3′ UTR re-
porter. We found that the luciferase activity of LATS1
Fig. 5 Knockdown MEIS2C/D inhibited nuclear accumulation of YAP by miR-1307-3p/LATS1/YAP axis. a Diagrams indicate putative miR-1307-3p
binding sites and corresponding mutant sites of LATS1 mRNA. LATS1 wild type mRNAs (WT) and corresponding mutant sequences (MUT), which
was cloned in luciferase reporter and co-transfection of either negative control or miR-1307-3p mimic in HEK293T cells. b LATS1 protein and
mRNA levels were measured by western blot and qRT-PCR in HEK293T cells transfected with miR-1307-3p mimic, anti-miR-1307-3p or negative
control (NC) miRNA. c HCC-LM3 cells were transfected with anti-miR-1307-3p, miR-1307-3p mimic, MEIS2C/D siRNA or controls. Then,
Immunoblotting of cell lysates was performed to examine phosphorylation of LATS1 and YAP. d HCC-LM3 cells were transfected with indicated
siRNA, miRNA and inhibitor. YAP intracellular localization investigated by immunofluorescence staining
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mRNA reporter was significantly inhibited when miR-
1307-3p was overexpressed. By contrast, when we mu-
tated the predicted binding site sequence for miR-1307-
3p, the expression of LATS1 was no longer affected by
miR-1307-3p (Fig. 5a, lower panel). Moreover, qRT-PCR
and western blot assays revealed that miR-1307-3p over-
expression dramatically reduced LATS1 levels in
HEK293T cells (Fig. 5b). As the regulatory molecules of
YAP in Hippo pathway, LATS1 can reduce the level of
phosphorylation of YAP. Based on this, si-MEIS2C/D,
miR-1307-3p mimic or anti-miR-1307-3p were used to
transfect HCC-LM3 cells, and LATS1 and YAP were de-
tected by Western blotting. When the expression of
MEIS2C/D or miR-1307-3p was inhibited, the protein
levels of LATS1 and phosphorylated LATS1 increased sig-
nificantly, while YAP, the substrate of LATS1, was de-
graded by LATS1 phosphorylation, resulting in an
increased in phosphorylation level (Fig. 5c). We also per-
formed immunofluorescence assay and confirmed that the
nuclear localization of YAP was weakened by si-MEIS2C/
D, miR-1307-3p mimic or anti-miR-1307-3p transfections
(Fig. 5d and Additional file 1: Figure S3B).
MEIS2C and MEIS2D collaborated with CDC73 in
differential modes
Since MEIS2D, not MEIS2C, could promote miR-1307
transcription, we speculate that MEIS2C/D may engage in
different molecular programs in the progression of HCC. In
order to distinguish the molecular function of MEIS2C and
MEIS2D, firstly we suppressed the expression of endogen-
ous MEIS2C/D in HCC-LM3 and MHCC97H cell lines,
and then transfected cells with anti-si-FlagMEIS2C and
anti-si-FlagMEIS2D plasmids, which are resistant to the
siRNA of MEIS2C/D (Fig. 6a and Additional file 1: Figure
S4B). We confirmed that MEIS2D suppressed YAP phos-
phorylation through LATS1/miR-1307-3p axis. Moreover,
protein level of SHP2 was decreased in anti-si-FlagMEIS2D
transfected group. Correspondently, the results of immuno-
fluorescence confirmed the nuclear translocation of YAP in
the MEIS2D rescued group (Fig. 6b and Additional
file 1: Figure S4A). Interestingly, Subsequent co-
immunoprecipitation experiment showed that
MEIS2D interacted with YAP and CDC73, while
MEIS2C could bind to β-catenin and CDC73 (Fig.
6c). Furthermore, immunofluorescence assay showed
that the nuclear localization of CDC73 and MEIS2C/
D was similar (Fig. 6d).
It is noteworthy that CDC73 is involved in different
transcription complex according to its phosphorylation
status [24, 27]. To address whether the phosphorylation
status of CDC73 could determine its association with
either MEIS2C or MEIS2D, we co-transfected HEK293T
cells with wild type (WT), dominant negative (DN,
C463S-SHP2), and constitutive active (CA, E76K-SHP2)
SHP2 together with CDC73 and MEIS2C/2D. By using
co-immunoprecipitation, we found that dominant nega-
tive SHP2 exogenous expression significantly suppressed
the interacting between CDC73 and MEIS2C, and the
interaction could be further enhanced by constitutive
active SHP2 (Fig. 6e left). Conversely, dominant negative
SHP2 facilitated the interaction between CDC73 and
MEIS2D, and this model can also be attenuated by
constitutive active SHP2 (Fig. 6e right). Previous study
reported that the phosphorylation-resistant (PR) CDC73
mutant could inhibit the interaction between CDC73
and other co-activators [27]. To explore the interaction
between CDC73 and MEIS2C/D, we expressed
CDC73PR mutant to immunoprecipitated Flag-MEIS2C
or Flag-MEIS2D in HEK 293 T cells. The results showed
that CDC73PR mutant could bind to MEIS2C as
opposed to MEIS2D (Fig. 6e right). These observations
collectively support that MEIS2C and MEIS2D involve
in different transcription complex: MEIS2C binds to β-
catenin and dephosphorylated CDC73. In contrast,
MEIS2D interacts with YAP and phosphorylated CDC73.
MEIS2C and MEIS2D promoted oncogene transcription in
human liver cancer
After we established the link between β-catenin, YAP,
CDC73, and MEIS2C/D, we sorted to determine the
downstream target genes of MEIS2C/D in HCC. From
database mining and screening [28], we identified six
MEIS2C/D downstream HCC-related genes, including
MYBL2, ANLN, FOXM1, BIRC5, PPP3CB and FZD7
(Fig. 7a and Additional file 1: Figure S5). Importantly,
knockdown of MEIS2C/D suppressed these genes ex-
pression in HCC cell lines (Fig. 7b). MYBL2, ANLN and
FOXM1 are known as target genes of YAP [29, 30],
while BIRC5, PPP3CB and FZD7 are related to βcatenin
signaling [31]. To further explorer the transcriptional
activation of these two MEIS2 isoforms, we suppressed
MEIS2C/D expression, and then ectopic expressed
MEIS2C and MEIS2D in HCC cells. Of note, MEIS2C
and MEIS2D could either promote gene transcription
synergistically or non-synergistically (Fig. 7c). In support
of the putative oncogenic activities of MEIS2C/D, higher
expression of these genes correlated with poorer progno-
sis in HCC patients (Fig. 7d, from www.proteinatlas.org).
Herein, we suggest that the activation of these genes ex-
erts the carcinogenic effect of MEIS2C/D and eventually
contributes to the development of HCC.
Discussion
Due to the molecular mechanism of HCC pathogenesis
remain unclear, many HCC patients are diagnosed as
metastasis and advanced stage, therefore missed the
opportunity for surgical treatment with good prognosis.
Deciphering the molecular mechanisms of carcinogenesis
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and metastasis is crucial for the development of new
therapeutic strategies in HCC. Most recent research indi-
cated that MEIS2D has the effect of promoting cancer
growth in Neuroblastoma [9, 15]. However, MEIS2 is
down-regulated in advanced prostate cancer [32]. In this
study, we report that the expression of MEIS2C/D was
significantly up-regulated and correlated with poor prog-
nosis which may serve as a promising therapeutic target in
personalized treatment of HCC. Based on the above re-
sults, we suppose that MEIS2C/D have significant impact
on tumor growth and metastasis in liver cancer cells. After
the expression of MEIS2C/D was attenuated in HCC cell
lines, proliferation and metastasis of these cells were
suppressed significantly in vitro, and the rate of subcuta-
neous tumorigenesis and metastasis in mice were also
significantly decreased in vivo.
MiR-1307-3p is a member of the miR-1307 sub-family
and plays an important role in breast cancer, colorectal
cancer and ovarian cancer, but the effect in HCC remain
unclear [14, 33, 34]. Moreover, accumulating studies
Fig. 6 MEIS2C/D interacted with β-catenin and YAP in different modes. a The rescue MEIS2C or MEIS2D cDNA clone, which is resistant to siRNA
interference, were used to rescue the MEIS2C/D expression after MEIS2C/D knockdown in HCC-LM3 cells. The level of phospho-LATS1, phospho-
YAP, phospho-CDC73 and total LATS1, YAP, CDC73 and SHP2 were detected in MEIS2C and MEIS2D rescued HCC-LM3 cells, respectively. b
Immunofluorescence staining for DAPI (Blue), YAP (Green) in HCC-LM3 cells. c Lysates were sequentially immune-precipitated (IP) from HCC-LM3
cells transfected with Flag-MEIS2C (left) or Flag-MEIS2D (right) and immunoblotted by CDC73, β-catenin and YAP antibody. d
Immunofluorescence images showing dual staining for CDC73 (Red) with Flag-MEIS2C or Flag-MEIS2D (Green) in HCC-LM3C cells. Merged picture
with sites of co-localization in yellow are shown. e SHP2 constructs [wildtype (WT), dominant negative (DN, C463S mutant), and constitutively
active (CA, E76K mutant)] and CDC73-Myc co-transfected with Flag-MEIS2C or Flag-MEIS2D in HEK293T cells. MEIS2 were immune-precipitated
from whole cell lysates and probed with Myc antibody to check the interaction with CDC73. f Phosphorylation-resistant (PR) CDC73-PR-Myc
mutant (CDC73-Y290/293F/315F-mutant) vector was transfected together with either Flag-MEIS2C or Flag-MEIS2D vector into HEK293T cells. Anti-
Myc immune-precipitates were analyzed by immunoblotting with anti-Myc and anti-Flag antibodies
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demonstrates that miR-1307-3p also relate to chemother-
apy resistant ovarian cancer [35, 36]. Considering the tran-
scriptional property of MEIS2 family and the correlation
expression between MEIS2C/D and miR-1307-3p in HCC
patients, our studies demonstrate that miR-1307-3p is one
of the key components of the MEIS2D circuit, whereby
the expression of miR-1307-3p is driven by MEIS2D in
HCC cells. MEIS2D and its synergistic molecule, PBX1,
could co-activate the expression of miR-1307. Moreover,
this proposal ensues that miR-1307-3p may act on its tar-
get gene and then help MEIS2D to further activate the sig-
naling pathway in HCC progression. After analysis the
potential target of miR-1307-3p, we identified that LATS1
as a functional target of miR-1307-3p. Consequently,
LATS1 suppression decreased the phosphorylation of
YAP and promoted the nucleation of YAP. In addition,
Fig. 7 MEIS2C/D promoted HCC related oncogene expression. a qRT-PCR analysis showed the RNA expression of MEIS2C/D was associated with
MYBL2, ANLN, FOXM1, BIRC5, PPP3CB and FZD7 expression were investigated in HCC cohort. b, c Gene expression were investigated by qRT-PCR
transfected with siMEIS2C/D or rescued expression with indicated antisi-FlagMEIS2 vectors in HCC-LM3 and MHCC97H cells. d Overall survival for
patients with high and low MEIS2C/D related gene expression in HCC cohorts (https://www.proteinatlas.org)
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YAP interacted with MEIS2D and phosphorylated
CDC73, then promoted transcription of downstream gene.
In miRNA biogenesis, miR-1307-5p and miR-1307-3p ma-
ture miRNA can be excised from the same pre-miRNA.
The expression of miRNA is controlled at transcriptional
and post-transcriptional levels. We identified that
MEIS2D promoted the transcription of miR-1307, but
post-transcriptional regulation of miR-1307-3p remains
elusive.
Although MEIS2C and MEIS2D play similar prolif-
erative role in tumor progression [9], it is important
to distinguish the pathological function between these
two isoforms. Our studies demonstrate that CDC73
interacts with either MEIS2C/β-catenin or MEIS2D/
YAP in a trimeric complex. Notably, it has been re-
ported that WNT, NOTCH and YAP are inversely
regulated by CDC73 according to its tyrosine phos-
phorylation status, and coordinates activation of genes
targeted by these complex [24, 27]. Correspondingly,
we confirmed that MEIS2C and MEIS2D exclusive
interacted with CDC73 also depending on its tyrosine
phosphorylation status.
SHP2, also known as PTPN11, has been elucidated its
crucial role in liver cancer stem cell expansion [23]. Reduc-
tion of SHP2 activity suppresses cancer cell growth and is
a potential target of cancer therapy [37]. However, it has
been reported that SHP2 localization regulated by YAP is
different in vitro and in vivo in hepatocellular carcinogen-
esis [38, 39]. Of note, we found that SHP2 decreased by
MEIS2C/D knockdown (Additional file 1: Figure S3A).
What is noteworthy is that the rescued MEIS2C may
increase the protein level of SHP2 (Fig. 6a), which in turn
enhances its interaction with CDC73 which act as an
important substrate of SHP2. Although MESI2C and
MEIS2D are competitive binding to CDC73, the present
works reveal that crosstalk also exist between these two
isoforms such as co-activation of FXOM1 and BIRC5
transcription.
Our clinical investigation revealed that the protein level
of MEIS2A/B was generally higher than that of MEIS2C/
D. So we speculate that MEIS2A/B also performs import-
ant biological functions in HCC. Considerable evidences
indicate that MEIS2A inhibits the development of neuro-
blastoma [15], and also our results confirmed that
MEIS2B overexpression inhibited the transcription of
miR-1307. However, our studies indicate that protein and
mRNA level of MEIS2A/B are no difference between
HCC and ANL tissues. Therefore the function of MESIA/
B remains to be further explored in HCC patients.
Taken together, our study shows that MEIS2D pro-
motes the development of HCC by miR-1307-3p/
LATS1/YAP circuit. On the other hand, MEIS2C bind
to dephosphorylated CDC73 and activate β-catenin in a
trimeric complex. Although these data imply that
MEIS2C/D might be a potential biomarker for HCC
treatment, further clinical investigation and more data
analysis are warranted to establish this point. The signifi-
cance of MEIS2C/D in HCC personalized medicine is
deserved to be further investigation.
Conclusions
Given Hepatocellular Carcinoma (HCC) is the third
leading cause of cancer death worldwide, defining the
regulatory mechanism is essential to decipher the patho-
genesis of HCC. Recent efforts have identified MEIS2 as
one of the key transcription factors in human cancers.
However, the regulatory mechanisms of MEIS2 activity
in HCC remain obscure. Herein, we describe that two of
MEIS2 alternatively spliced isoforms, MEIS2C and
MEIS2D, expression dramatically increased in HCC
patient, and negatively correlated with the prognosis of
HCC patients. Using an in vivo and in vitro approach,
we show that MEIS2C and MEIS2D promote the prolif-
eration and metastasis of hepatoma cells via Hippo/YAP
and Wnt/β-catenin signaling. This provides further
insights into the complex regulatory network of MEIS2
and further support for developments of MEIS2 iso-
forms–specific inhibitors for HCC treatment.
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